Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Acute Leukemias

GSK3 is a regulator of RAR-mediated differentiation

Leukemia volume 26, pages 1277–1285 (2012)Cite this article

Subjects

Abstract

Acute myeloid leukemia (AML) is the most common form of leukemia in adults. Unfortunately, the standard therapeutic agents used for this disease have high toxicities and poor efficacy. The one exception to these poor outcomes is the use of the retinoid, all-trans retinoic acid (ATRA), for a rare subtype of AML (APL). The use of the differentiation agent, ATRA, in combination with low-dose chemotherapy leads to the long-term survival and presumed cure of 75–85% of patients. Unfortunately ATRA has not been clinically useful for other subtypes of AML. Though many non-APL leukemic cells respond to ATRA, they require significantly higher concentrations of ATRA for effective differentiation. Here we show that the combination of ATRA with glycogen synthase kinase 3 (GSK3) inhibition significantly enhances ATRA-mediated AML differentiation and growth inhibition. These studies have revealed that ATRA’s receptor, the retinoic acid receptor (RAR), is a novel target of GSK3 phosphorylation and that GSK3 can impact the expression and transcriptional activity of the RAR. Overall, our studies suggest the clinical potential of ATRA and GSK3 inhibition for AML and provide a mechanistic framework to explain the promising activity of this combination regimen.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Estey EH . General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia. Semin Hematol 2006; 43: 89–95.

    Article  PubMed  Google Scholar 

  2. Tallmann MS . Curative therapeutic approaches to APL. Ann Hematol 2004; 83 (Suppl 1): S81–S82.

    PubMed  Google Scholar 

  3. Wald DN, Vermaat HM, Zang S, Lavik A, Kang Z, Peleg G et al. Identification of 6-benzylthioinosine as a myeloid leukemia differentiation-inducing compound. Cancer Res 2008; 68: 4369–4376.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Gupta K, Chakrabarti A, Rana S, Ramdeo R, Roth B, Agarwal M et al. Securinine, a myeloid differentiation agent with therapeutic potential for AML. PLoS One 2011; 6: e21203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Wang Z, Smith KS, Murphy M, Piloto O, Somervaille TC, Cleary ML . Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 2008; 455: 1205–1209.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Holmes T, O’Brien TA, Knight R, Lindeman R, Shen S, Song E et al. Glycogen synthase kinase-3beta inhibition preserves hematopoietic stem cell activity and inhibits leukemic cell growth. Stem Cells 2008; 26: 1288–1297.

    Article  CAS  PubMed  Google Scholar 

  7. Song EY, Palladinetti P, Klamer G, Ko KH, Lindeman R, O’Brien TA et al. Glycogen synthase kinase--3beta inhibitors suppress leukemia cell growth. Exp Hematol 2010; 38: 908–921 e901.

    Article  CAS  PubMed  Google Scholar 

  8. Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A . Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 2009; 156: 885–898.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Doble BW, Woodgett JR . GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003; 116 (Part 7): 1175–1186.

    Article  CAS  PubMed  Google Scholar 

  10. Grimes CA, Jope RS . The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001; 65: 391–426.

    Article  CAS  PubMed  Google Scholar 

  11. Hernandez F, Nido JD, Avila J, Villanueva N . GSK3 inhibitors and disease. Mini Rev Med Chem 2009; 9: 1024–1029.

    Article  CAS  PubMed  Google Scholar 

  12. Medina M, Castro A . Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. Curr Opin Drug Discov Devel 2008; 11: 533–543.

    CAS  PubMed  Google Scholar 

  13. Guzman ML, Li X, Corbett CA, Rossi RM, Bushnell T, Liesveld JL et al. Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood 2007; 110: 4436–4444.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Zhou Y, Uddin S, Zimmerman T, Kang JA, Ulaszek J, Wickrema A . Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3. Leuk Lymphoma 2008; 49: 1945–1953.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Martinez A . Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs. Med Res Rev 2008; 28: 773–796.

    Article  CAS  PubMed  Google Scholar 

  16. Collins SJ, Ruscetti FW, Gallagher RE, Gallo RC . Normal functional characteristics of cultured human promyelocytic leukemia cells (HL-60) after induction of differentiation by dimethylsulfoxide. J Exp Med 1979; 149: 969–974.

    Article  CAS  PubMed  Google Scholar 

  17. Newburger PE, Chovaniec ME, Greenberger JS, Cohen HJ . Functional changes in human leukemic cell line HL-60. A model for myeloid differentiation. J Cell Biol 1979; 82: 315–322.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Collins SJ, Bodner A, Ting R, Gallo RC . Induction of morphological and functional differentiation of human promyelocytic leukemia cells (HL-60) by componuds which induce differentiation of murine leukemia cells. Int J Cancer 1980; 25: 213–218.

    Article  CAS  PubMed  Google Scholar 

  19. Guglielmo P, Pagano MC, Giustolisi R . [The nitroblue tetrazolium activated test in the study of granulocytic function. Proposed methodology]. Boll Soc Ital Biol Sper 1980; 56: 183–187.

    CAS  PubMed  Google Scholar 

  20. Newburger PE, Speier C, Borregaard N, Walsh CE, Whitin JC, Simons ER . Development of the superoxide-generating system during differentiation of the HL-60 human promyelocytic leukemia cell line. J Biol Chem 1984; 259: 3771–3776.

    CAS  PubMed  Google Scholar 

  21. Prakash R . A review of the hematologic side effects of lithium. Hosp Community Psychiatry 1985; 36: 127–128.

    CAS  PubMed  Google Scholar 

  22. Dixon JF, Hokin LE . Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex. Proc Natl Acad Sci USA 1998; 95: 8363–8368.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Grandjean EM, Aubry JM . Lithium: updated human knowledge using an evidence-based approach. Part II: clinical pharmacology and therapeutic monitoring. CNS Drugs 2009; 23: 331–349.

    Article  CAS  PubMed  Google Scholar 

  24. MacAulay K, Blair AS, Hajduch E, Terashima T, Baba O, Sutherland C et al. Constitutive activation of GSK3 down-regulates glycogen synthase abundance and glycogen deposition in rat skeletal muscle cells. J Biol Chem 2005; 280: 9509–9518.

    Article  CAS  PubMed  Google Scholar 

  25. Li X, Friedman AB, Zhu W, Wang L, Boswell S, May RS et al. Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder. Biol Psychiatry 2007; 61: 216–222.

    Article  CAS  PubMed  Google Scholar 

  26. Si J, Mueller L, Collins SJ . GSK3 inhibitors enhance retinoic acid receptor activity and induce the differentiation of retinoic acid-sensitive myeloid leukemia cells. Leukemia 2011; 25: 1914–1918.

    Article  CAS  PubMed  Google Scholar 

  27. Farboud B, Privalsky ML . Retinoic acid receptor-alpha is stabilized in a repressive state by its C-terminal, isotype-specific F domain. Mol Endocrinol 2004; 18: 2839–2853.

    Article  CAS  PubMed  Google Scholar 

  28. Bushue N, Wan YJ . Retinoid pathway and cancer therapeutics. Adv Drug Deliv Rev 2010; 62: 1285–1298.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Soprano DR, Qin P, Soprano KJ . Retinoic acid receptors and cancers. Annu Rev Nutr 2004; 24: 201–221.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA

    K Gupta, L Sun, R Aguilera & D N Wald

  2. Cleveland Clinic Foundation, Cleveland, OH, USA

    F Gulen

  3. Cleveland Leukemia Therapeutics, Cleveland, OH, USA

    A Chakrabarti & M K Agarwal

  4. Center for Proteomics and Bioinformatics Case Western Reserve University School of Medicine, Cleveland, OH, USA

    J Kiselar

Authors
  1. K Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F Gulen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Aguilera
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Chakrabarti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Kiselar
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M K Agarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D N Wald
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D N Wald.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gupta, K., Gulen, F., Sun, L. et al. GSK3 is a regulator of RAR-mediated differentiation. Leukemia 26, 1277–1285 (2012). https://doi.org/10.1038/leu.2012.2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2012.2

Keywords

This article is cited by

Search

Advanced search

Quick links